Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Geron Corporation (GERN)

2.22   0.02 (0.91%) 11-25 13:00
Open: 2.19 Pre. Close: 2.2
High: 2.24 Low: 2.185
Volume: 626,232 Market Cap: 846(M)

Technical analysis

as of: 2022-11-25 1:57:22 PM
Overall:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.89     One year: 3.38
Support: Support1: 2.15    Support2: 1.96
Resistance: Resistance1: 2.48    Resistance2: 2.89
Pivot: 2.2
Moving Average: MA(5): 2.21     MA(20): 2.2
MA(100): 2.25     MA(250): 1.67
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 68.3     %D(3): 64.3
RSI: RSI(14): 48.8
52-week: High: 3.05  Low: 0.99
Average Vol(K): 3-Month: 3,568 (K)  10-Days: 2,360 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GERN ] has closed below upper band by 45.0%. Bollinger Bands are 51.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.29 - 2.3 2.3 - 2.31
Low: 2.16 - 2.17 2.17 - 2.18
Close: 2.18 - 2.2 2.2 - 2.22

Company Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Headline News

Fri, 18 Nov 2022
Should You Add Geron Corporation (GERN) Stock to Your Portfolio Friday? - InvestorsObserver

Mon, 07 Nov 2022
Geron to Participate in Stifel 2022 Healthcare Conference - Geron (NASDAQ:GERN) - Benzinga

Fri, 04 Nov 2022
Geron (GERN) Q3 2022 Earnings Call Transcript - The Motley Fool

Thu, 03 Nov 2022
Geron Corporation (GERN) Q3 2022 Earnings Call Transcript - Seeking Alpha

Fri, 28 Oct 2022
What is the Market's View on Geron Corporation (GERN) Stock's Price and Volume Trends Friday? - InvestorsObserver

Thu, 27 Oct 2022
Geron to Announce Third Quarter 2022 Financial Results on November 3, 2022 - Business Wire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 381 (M)
% Held by Insiders 3.5021e+008 (%)
% Held by Institutions 4.1 (%)
Shares Short 13,460 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.2031e+008
EPS Est Next Qtl -0.06
EPS Est This Year -0.19
EPS Est Next Year -0.02
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -7
Return on Assets (ttm) 865.6
Return on Equity (ttm) -32.7
Qtrly Rev. Growth 1.53e+006
Gross Profit (p.s.) 226.97
Sales Per Share -133.02
EBITDA (p.s.) -2.89474e+006
Qtrly Earnings Growth -0.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -114 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -1.2
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 6.02

Stock Dividends

Dividend 0
Forward Dividend 1.65e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.